Discover comprehensive details about Benznidazole, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Benznidazole is a nitroimidazole antiprotozoal agent prescribed to treat children of 2 to 12 years of age suffering from American trypanosomiasis or Chagas disease which is caused by Trypanosoma cruzi ...

progression A 40 to 80 day treatment with the antiparasitic medication benznidazole significantly reduced parasite activity in the blood, but not progression, of serious heart problems over a 5-year ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to benznidazole for the treatment of Chagas disease among children aged 2 ...

The US Food and Drug Administration (FDA) has granted accelerated approval to benznidazole (Chemo Research, SL) for treatment of children aged 2 to 12 years with Chagas disease, becoming the first ...

A long-term follow-up study among patients with chronic Chagas disease showed that the time to positive molecular detection of the disease was significantly shorter with posaconazole than with ...

After dropping $2 million on a Wu-Tang Clan album, the pharmaceutical executive Martin Shkreli has found a new project: making an essential treatment unaffordable for poor immigrants from Latin ...

Brazil stands accused of neglecting thousands of people with Chagas disease due to a lack of action that will led to a shortage of the only first-line drug used in most endemic countries. Brazil ...

The Food and Drug Administration recently approved the first U.S. treatment for childhood cases of Chagas disease — a parasite-driven illness that, over time and unless treated early, can cause ...

Last week, the Food and Drug Administration announced its approval of the drug benznidazole, which is used to treat a parasitic disease that afflicts about 300,000 Americans and that, left untreated, ...

SOUTH SAN FRANCISCO, Calif., Dec. 3, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (KBIO), today announced that it has signed an agreement to acquire a benznidazole program for the treatment of ...